Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform level de-risking event"

March 13, 2026 1:05 PM

Morgan Stanley analyst Maxwell Skor reiterated an Overweight rating and $12.00 price target on Sana Biotechnology (NASDAQ: SANA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found